Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 5/20 | 0.56 |
| ▸ | PDE3A | Q14432 | 5/20 | 0.56 |
| ▸ | CA12 | O43570 | 2/20 | 0.46 |
| ▸ | CA9 | Q16790 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | TNKS2 | Q9H2K2 | 4/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10727584 | 0.82 | PDE3B (0.53) | PDE3BPDE3ACA12CA9KDM4E | |
| SCHEMBL24996942 | 0.80 | PDE3B (0.43) | PDE3BPDE3ACA12CA9KDM4E | |
| SCHEMBL24996736 | 0.80 | PDE3B (0.42) | PDE3BPDE3ACA12CA9KDM4E | |
| SCHEMBL10726022 | 0.78 | GAA (0.46) | PDE3BPDE3ACA12CA9KDM4E | |
| SCHEMBL9350602 | 0.77 | PDE3B (0.49) | PDE3BPDE3ACA12CA9LMNA | |
| SCHEMBL10724755 | 0.74 | PDE3B (0.69) | PDE3BPDE3ACA12CA9KDM4E | |
| SCHEMBL3177677 | 0.73 | NPC1 (0.51) | PDE3BPDE3AKDM4ELMNAHTT | |
| SCHEMBL10730343 | 0.72 | PDE3B (0.43) | PDE3BPDE3ACA12CA9GAA | |
| Medorinone SCHEMBL121782 | 0.72 | PDE3B (1.00) | PDE3BPDE3AKDM4EALDH1A1HPGD | |
| SCHEMBL3184818 | 0.72 | KDM4E (0.49) | KDM4ELMNAHTTGAASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3889152-A1 | HETEROAROMATIC DERIVATIVES FOR USE AS REGULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. (CN) | 2021-10-06 | — | — | EP | disclosed |
| WO-2020108613-A1 | HETEROAROMATIC DERIVATIVES FOR USE AS REGULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF | 江苏豪森药业集团有限公司 | 2020-06-04 | — | — | WO | disclosed |
| US-8258301-B2 | Urotensin II receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-09-04 | — | — | US | disclosed |
| US-8258301-B2 | Urotensin II receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-09-04 | — | — | US | disclosed |
| US-20100121051-A1 | UROTENSIN II RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-05-13 | — | — | US | disclosed |
| US-20100121051-A1 | UROTENSIN II RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-05-13 | — | — | US | disclosed |
| US-20100010035-A1 | Novel Dual Action Receptors Antagonists (Dara) at the Ati and Eta Receptors | TORRENT PHARMACEUTICALS LTD. (IN) | 2010-01-14 | — | — | US | disclosed |
| EP-1996588-A1 | NOVEL DUAL ACTION RECEPTORS ANTAGONISTS (DARA) AT THE ATI AND ETA RECEPTORS | Torrent Pharmaceuticals Ltd (IN) | 2008-12-03 | — | — | EP | disclosed |
| WO-2008144268-A1 | UROTENSIN II RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-11-27 | — | — | WO | disclosed |
| WO-2007100295-A1 | NOVEL DUAL ACTION RECEPTORS ANTAGONISTS (DARA) AT THE ATI AND ETA RECEPTORS | TORRENT PHARMACEUTICALS LTD (IN) | 2007-09-07 | — | — | WO | disclosed |
| US-5294620-A | Hypotensive agents or compounds for cardiovascular disorders | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1994-03-15 | — | — | US | disclosed |
| US-5281613-A | Heterocyclic ring substituted benzofuran, benzothiofuran, or indole derivative | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1994-01-25 | — | — | US | disclosed |
| US-5217976-A | Hypotensive agents, congestive heart failure | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100010035-A1 | Novel Dual Action Receptors Antagonists (Dara) at the Ati and Eta Receptors | EDNRA, EDNRB, AGTR1 | PDE3B 811/4885PDE3A 822/4885CA12 4362/4885 |
| US-20100121051-A1 | UROTENSIN II RECEPTOR ANTAGONISTS | UTS2R, AGTR1, AGTR2 | PDE3B 2879/4885PDE3A 2180/4885CA12 3820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.